Inhibrx Biosciences Inc. stocks have been trading up by 28.89 percent amid heightened optimism from the most impactful biotech news
Click Here for a Millionaire's POV on Trading INBX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Interim Phase 1/2 data for ozekibart plus FOLFIRI in heavily pretreated metastatic colorectal cancer showed a 20% objective response rate, 5.5‑month median progression-free survival, and 87% disease control with manageable safety.
- The company plans an FDA meeting in the second half of 2026 to launch a first-line registrational colorectal cancer trial and is exploring accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma.
- A Biologics License Application is already on file for ozekibart in conventional chondrosarcoma after a positive registrational trial.
- Stifel initiated coverage of Inhibrx Biosciences with a Buy rating and a $150 price target, pointing to strong clinical progress for ozekibart and INBRX-106.
Live Update At 12:32:20 EDT: On Wednesday, April 22, 2026 Inhibrx Biosciences Inc. stock [NASDAQ: INBX] is trending up by 28.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
INBX has been trading like a classic biotech momentum name. In a few weeks it ran from the high $50s to a peak above $150 before closing at $108.37 on 2026/04/22. That’s a massive range, and it tells traders one thing: volatility is the edge here.
The multi-day chart shows INBX grinding higher through late March and early April, then exploding after clinical and analyst headlines. Pullbacks toward the low $80s repeatedly found buyers before yesterday’s gap-and-slam action, where INBX opened at $147.50, tagged $155.29, then flushed to $100 intraday. That kind of intraday range is a day trader’s playground but a swing trader’s risk management test.
More Breaking News
- ORBS Stock Pulls Back As Traders Watch Key Support
- EVTL Stock Sinks As Vertical Aerospace Faces Funding And Legal Pressures
- HTZ Stock Sinks Over 10% In Sudden Intraday Slide
- DARE Bioscience Jumps As DARE to PLAY Launch and Pipeline Catalysts Draw Focus
Fundamentals confirm this is a high-beta biotech story, not a value play. INBX posted only about $1.3M in revenue with a price-to-sales ratio north of 900 and deeply negative margins. The company is burning cash, with roughly -$30M in quarterly operating cash flow, but it ended the last reported quarter with $124.22M in cash and a current ratio of 3.9. For traders, that cash runway plus a leveraged balance sheet means the story lives or dies on news, not on near-term earnings.
Why Traders Are Watching INBX Right Now
Traders are crowding into INBX because the news flow finally lines up with the chart. Inhibrx Biosciences reported updated interim Phase 1/2 data for ozekibart (INBRX-109) plus FOLFIRI in heavily pretreated metastatic colorectal cancer. A 20% objective response rate and 87% disease control in that kind of tough population is not noise. For a small-cap biotech like INBX, this is a real de‑risking event.
The median progression-free survival of 5.5 months, combined with what’s described as a manageable safety profile, gives INBX a clear narrative: this isn’t just another early-stage signal, it’s a backbone for registrational plans. The company is already lining up an FDA meeting in the second half of 2026 to push ozekibart into a first-line colorectal cancer trial. On top of that, INBX is exploring accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma.
Traders also care that INBX has already submitted a BLA for ozekibart in conventional chondrosarcoma after a positive registrational trial. That moves the story from “maybe someday” to “regulatory clock is ticking.” Biotech runs often cluster around such milestones.
Layer on top the Street’s validation: Stifel launched coverage on Inhibrx Biosciences with a Buy rating and a $150 price target, highlighting the same elements traders are watching—ozekibart’s data set, proof-of-concept in chondrosarcoma, and the INBRX-106 program. New coverage like this can pull fresh trading capital into INBX as momentum algos and discretionary biotech traders scan for names with strong catalysts and clear analyst narratives.
Conclusion
For active traders, INBX now sits at the crossroads of big science and big volatility. The ozekibart data in colorectal cancer, the BLA in conventional chondrosarcoma, and the plan for a first-line registrational trial give Inhibrx Biosciences a catalyst stack that many small biotechs lack. That is why INBX has been swinging wildly between triple-digit prices intraday.
At the same time, the financials remind everyone what this really is: a development-stage biotech burning over $30M in quarterly cash with minimal revenue and heavy losses. INBX depends on continued access to capital and on clinical and regulatory wins. Stifel’s Buy rating and $150 price target show that at least one Wall Street shop sees significant upside, but traders know analyst targets do not remove risk—they just frame it.
In this kind of name, the edge is preparation, not prediction. Tim Sykes likes to say, “Volatility is opportunity if you’re prepared, but it’s disaster if you’re lazy.” That mindset lines up with the day-trading approach many use on volatile tickers like INBX; as Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” INBX fits those lines perfectly. The ticker offers clean catalysts, huge ranges, and clear levels on the chart. For traders who study the filings, track the FDA timeline, and cut losses fast, Inhibrx Biosciences is a prime educational case study in how clinical headlines can drive powerful—yet fragile—momentum in biotech trading.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.